Catalyst Wire Dossier Catalyst Wire Dossier

MK-0431D

sitagliptin and simvastatin fixed-dose combination · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-0431D, covering 2014-10-22 to 2014-10-22. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266) [Phase 3]

See pricing